Macrolide treatment of Non-Eosinophilic Asthma

A double blind randomised controlled study of the anti-inflammatory effects of clarithromycin 500mg twice daily for 8 weeks in adults with symptomatic Non-Eosinophilic Asthma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000318684

Acronym

NEAT

Enrollment

Registered

2005-09-06

Start date

2004-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Clarithromycin 500mg twice daily for 8 weeks

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Symptomatic stable asthma, airway hyperresponsiveness and or bronchodilator response.

Exclusion criteria

Hypersensitivity to Macrolides, Other Respiratory Disease, Taking antihistamine medication, Pregnancy, Breast Feeding, Oral Corticosteroid use in past month, Antibiotic use in past month.

Outcome results